Cargando…

1382. Acid-Fast Bacilli Testing Trends at 43 In- and Outpatient Facilities and Nontuberculous Mycobacterial Pulmonary Isolation Rate, United States, 2009–2015

BACKGROUND: The prevalence of nontuberculous mycobacterial pulmonary disease (NTM PD) is increasing in the United States and globally. The reasons for this increase are not clear but could be related to both gained awareness leading to increased mycobacterial testing, or to a true NTM PD increase. T...

Descripción completa

Detalles Bibliográficos
Autores principales: Ling Lai, Yi, Ricotta, Emily, Olivier, Kenneth, Kadri, Sameer S, Prevots, D Rebecca
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6809242/
http://dx.doi.org/10.1093/ofid/ofz360.1246
_version_ 1783461937496981504
author Ling Lai, Yi
Ricotta, Emily
Olivier, Kenneth
Kadri, Sameer S
Prevots, D Rebecca
author_facet Ling Lai, Yi
Ricotta, Emily
Olivier, Kenneth
Kadri, Sameer S
Prevots, D Rebecca
author_sort Ling Lai, Yi
collection PubMed
description BACKGROUND: The prevalence of nontuberculous mycobacterial pulmonary disease (NTM PD) is increasing in the United States and globally. The reasons for this increase are not clear but could be related to both gained awareness leading to increased mycobacterial testing, or to a true NTM PD increase. To further examine the role of testing rates in the observed increase, we studied trends in Acid-Fast Bacteria (AFB) testing and NTM isolation positivity using a large Electronic Health Record (EHR) dataset in the United States. METHODS: Using the Cerner Health Facts EHR dataset, we extracted microbiologic, demographic, and clinical data for patient encounters (inpatient or outpatient), with ≥1 orders for AFB respiratory cultures. The analysis was limited to the 43 facilities reporting continuously for the period 2009–2015. A patient with at least one AFB test was considered tested (AFB) and a patient with at least one pathogenic NTM respiratory isolate was considered positive. Trends in AFB testing and NTM positivity were estimated using log-linked Poisson regression (P < 0.05). RESULTS: From 2009 through 2015, of 14.8 million patients, 65,010 had 142,315 AFB tests, averaging 2.2 AFB tests/patient, for an overall testing prevalence of 0.43%; the annual testing prevalence remained unchanged during the study period (P = 0.44) (Figure 1). Of the 65,010 patients with AFB tests, 3,942 (6.1%) had ≥1 pathogenic NTM species, for an overall pulmonary NTM isolation prevalence of 2.7/10,000 patients represented in Cerner Health Facts dataset. Of the patients that had at least one pathogenic NTM, 3,094 (78%) had M. avium complex, and 265 (7%) had M. abscessus/chelonae, (Figure 2). Among patients with at least 1 NTM-positive culture, 138 patients had concomitant growth of M. tuberculosis. CONCLUSION: Increases in NTM PD are not explained by increases in AFB testing, which remained constant in the population represented here. This study was funded in part by the Division of Intramural Research, NIAID, NIH. [Image: see text] [Image: see text] DISCLOSURES: All authors: No reported disclosures.
format Online
Article
Text
id pubmed-6809242
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-68092422019-10-28 1382. Acid-Fast Bacilli Testing Trends at 43 In- and Outpatient Facilities and Nontuberculous Mycobacterial Pulmonary Isolation Rate, United States, 2009–2015 Ling Lai, Yi Ricotta, Emily Olivier, Kenneth Kadri, Sameer S Prevots, D Rebecca Open Forum Infect Dis Abstracts BACKGROUND: The prevalence of nontuberculous mycobacterial pulmonary disease (NTM PD) is increasing in the United States and globally. The reasons for this increase are not clear but could be related to both gained awareness leading to increased mycobacterial testing, or to a true NTM PD increase. To further examine the role of testing rates in the observed increase, we studied trends in Acid-Fast Bacteria (AFB) testing and NTM isolation positivity using a large Electronic Health Record (EHR) dataset in the United States. METHODS: Using the Cerner Health Facts EHR dataset, we extracted microbiologic, demographic, and clinical data for patient encounters (inpatient or outpatient), with ≥1 orders for AFB respiratory cultures. The analysis was limited to the 43 facilities reporting continuously for the period 2009–2015. A patient with at least one AFB test was considered tested (AFB) and a patient with at least one pathogenic NTM respiratory isolate was considered positive. Trends in AFB testing and NTM positivity were estimated using log-linked Poisson regression (P < 0.05). RESULTS: From 2009 through 2015, of 14.8 million patients, 65,010 had 142,315 AFB tests, averaging 2.2 AFB tests/patient, for an overall testing prevalence of 0.43%; the annual testing prevalence remained unchanged during the study period (P = 0.44) (Figure 1). Of the 65,010 patients with AFB tests, 3,942 (6.1%) had ≥1 pathogenic NTM species, for an overall pulmonary NTM isolation prevalence of 2.7/10,000 patients represented in Cerner Health Facts dataset. Of the patients that had at least one pathogenic NTM, 3,094 (78%) had M. avium complex, and 265 (7%) had M. abscessus/chelonae, (Figure 2). Among patients with at least 1 NTM-positive culture, 138 patients had concomitant growth of M. tuberculosis. CONCLUSION: Increases in NTM PD are not explained by increases in AFB testing, which remained constant in the population represented here. This study was funded in part by the Division of Intramural Research, NIAID, NIH. [Image: see text] [Image: see text] DISCLOSURES: All authors: No reported disclosures. Oxford University Press 2019-10-23 /pmc/articles/PMC6809242/ http://dx.doi.org/10.1093/ofid/ofz360.1246 Text en © The Author(s) 2019. Published by Oxford University Press on behalf of Infectious Diseases Society of America. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Abstracts
Ling Lai, Yi
Ricotta, Emily
Olivier, Kenneth
Kadri, Sameer S
Prevots, D Rebecca
1382. Acid-Fast Bacilli Testing Trends at 43 In- and Outpatient Facilities and Nontuberculous Mycobacterial Pulmonary Isolation Rate, United States, 2009–2015
title 1382. Acid-Fast Bacilli Testing Trends at 43 In- and Outpatient Facilities and Nontuberculous Mycobacterial Pulmonary Isolation Rate, United States, 2009–2015
title_full 1382. Acid-Fast Bacilli Testing Trends at 43 In- and Outpatient Facilities and Nontuberculous Mycobacterial Pulmonary Isolation Rate, United States, 2009–2015
title_fullStr 1382. Acid-Fast Bacilli Testing Trends at 43 In- and Outpatient Facilities and Nontuberculous Mycobacterial Pulmonary Isolation Rate, United States, 2009–2015
title_full_unstemmed 1382. Acid-Fast Bacilli Testing Trends at 43 In- and Outpatient Facilities and Nontuberculous Mycobacterial Pulmonary Isolation Rate, United States, 2009–2015
title_short 1382. Acid-Fast Bacilli Testing Trends at 43 In- and Outpatient Facilities and Nontuberculous Mycobacterial Pulmonary Isolation Rate, United States, 2009–2015
title_sort 1382. acid-fast bacilli testing trends at 43 in- and outpatient facilities and nontuberculous mycobacterial pulmonary isolation rate, united states, 2009–2015
topic Abstracts
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6809242/
http://dx.doi.org/10.1093/ofid/ofz360.1246
work_keys_str_mv AT linglaiyi 1382acidfastbacillitestingtrendsat43inandoutpatientfacilitiesandnontuberculousmycobacterialpulmonaryisolationrateunitedstates20092015
AT ricottaemily 1382acidfastbacillitestingtrendsat43inandoutpatientfacilitiesandnontuberculousmycobacterialpulmonaryisolationrateunitedstates20092015
AT olivierkenneth 1382acidfastbacillitestingtrendsat43inandoutpatientfacilitiesandnontuberculousmycobacterialpulmonaryisolationrateunitedstates20092015
AT kadrisameers 1382acidfastbacillitestingtrendsat43inandoutpatientfacilitiesandnontuberculousmycobacterialpulmonaryisolationrateunitedstates20092015
AT prevotsdrebecca 1382acidfastbacillitestingtrendsat43inandoutpatientfacilitiesandnontuberculousmycobacterialpulmonaryisolationrateunitedstates20092015